Chuo Li
Tianjin, 301600, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Th17-driven CD8+ T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy.
Journal: Cell death & disease
Published: July 03, 2025
LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 12, 2024
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 16, 2024
Myeloid leukemia-derived galectin-1 downregulates CAR expression to hinder cytotoxicity of CAR T cells.
Journal: Journal of translational medicine
Published: September 14, 2023
C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial.
Journal: Nature communications
Published: September 13, 2023
Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.
Journal: Frontiers in oncology
Published: September 16, 2021
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.
Journal: Journal of hematology & oncology
Published: May 31, 2021
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
Journal: Blood cancer journal
Published: January 21, 2021
Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.
Journal: Frontiers in oncology
Published: December 10, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026